DISHMAN

DISHMAN: Members of the Exchange are hereby informed that the trading in Equity Shares of Dishman Pharmaceuticals and Chemicals Limited shall be suspended w.e.f. May 30, 2017 (i.e. closing hours of trading on May 29, 2017) on account of Scheme of Amalgamation of Dishman Pharmaceuticals and Chemicals Limited with Carbogen Amcis (India) Limited.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Board of directors of Amalgamated entity i.e Dishman Carbogen Amcis Limited, in its meeting held on May 19, 2017 has fixed Record Date as May 31, 2017 for the purpose of deciding the members who shall be eligible for allotment of equity shares of the amalgamated entity, Dishman Carbogen Amcis Limited to the shareholders of erstwhile Dishman Pharmaceuticals and Chemicals Limited ("DPCL") in the ratio of 1:1 i.e. Share Exchange Ratio [1 (One) fully paid-up Equity Share of Rs.2/- (Rupees Two only) each of DCAL, for e

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Investor Presentation

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2017.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Credit Rating

Bhadra Raj Holdings Private Limited has submitted to the Exchange vide letter dated April 06, 2017 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Bhadra Raj Holdings Pvt Ltd has submitted to the Exchange, vide letter dated April 5, 2017 a copy of disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

The Exchange has sought clarification from Dishman Pharmaceuticals and Chemicals Limited with respect to recent news item captioned "US FDA Approves Zejula Capsules.". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Dishman Pharmaceuticals and Chemicals Limited has submitted their response.

The Exchange has sought clarification from Dishman Pharmaceuticals and Chemicals Limited with respect to recent news item captioned "US FDA Approves Zejula Capsules.". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Update on Scheme of Arrangement and Amalgamation amongst Dishman Pharmaceuticals and Chemicals Ltd., Carbogen Amcis (India) Limited and Dishman Care Limited and their respective Shareholders & Creditors.

Bhadra Raj Holdings Private Limited has submitted to the Exchange, vide letter dated March 24, 2017 a copy of disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding outcome of meeting of the Board of Directors of the Company held on March 17, 2017.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Update on Scheme of Arrangement and Amalgamation amongst Dishman Pharmaceuticals and Chemicals Ltd., Carbogen Amcis (India) Limited and Dishman Care Limited and their respective Shareholders & Creditors

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that In reference to Company's intimation dated March 08, 2017, intimation regarding fire took place at one of the units (Unit No.7) at Company's Bavla facility, this is to further inform that there will be no impact on the production in any of the other units located at said Bavla facility.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that there was a fire incident at one of the units (Unit No.7) at the Company's Bavla facility on March 07, 2017 late evening and it had been brought under control. Health and safety of the people is always prime concern and that has been achieved. The Company also do not see any major financial impact due to the incident. Moreover, the Company has an insurance policy for the assets damage and the loss of profit.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Investor Presentation

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Board of Directors, at its meeting held on February 13, 2017 has declared an lnterim dividend at 60% (i.e. Rs. 1.20 per equity share of Rs.2.00 each) on 16,13,94,272 equity shares of the Company for the financial year 2016-2017.The interim dividend shall be paid to the members entitled thereto, on and from February 25, 2017.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company has fixed Record Date as February 21, 2017 for purpose of Payment of lnterim Dividend for the financial year 2016-17, if declared by the Board of Directors of the Company.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company's Bavla facility was successfully inspected by the US FDA in July, 2016, which was intimated to the stock exchanges on July 9, 2016. In this regard, we are pleased to share that the Company has received the Establishment Inspection Report (EIR) from the US FDA for this facility today.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Order from Hon'ble High Court of Gujarat sanctioning Scheme of Arrangement and Amalgamation amongst Dishman Pharmaceuticals and Chemicals Ltd., Carbogen Amcis (India) Limited and Dishman Care Limited and their respective Shareholders & Creditors

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of Newspaper Publication of Transfer of Equity Shares of the Company to Investor Education and Protection Fund (IEPF) Suspense Account.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of INVESTORS PRESENTATION ON UNAUDITED FINANCIAL RESULT REGULATION: 30

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Intimation of Conference Call.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a Copy of Limited Review for the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Intimation of Conference Call.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that as per Code of Conduct for prevention of lnsider Trading adopted by the Company under SEBI (Prohibition of lnsider Trading) Regulations , 2015, the trading window shall remain closed from October 19,2016 to October 29, 2016 (both days inclusive) for all the connected persons.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding the detailed voting results of the Annual general Meeting of the Company held on September 27, 2016 along with the scrutinizers report.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on September 27, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange the newspaper advertisement regarding hearing of petition.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of notice of Annual General Meeting of the members of the Company to be held on September 27, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company has fixed Book Closure from September 20, 2016 to September 27, 2016 for the purpose of the Annual General Meeting of the Company scheduled to be held on September 27, 2016

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that Ms. Shrima G. Dave, Asst. company Secretary and compliance officer of the company, is appointed as a "Company Secretary and Compliance officer" of the Company w.e.f August 24, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Transcript of Conference Call - Quarter Ended June 30, 2016.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the details of voting results of the Court Convened Meeting of the Company held on the August 5, 2016 along with Report of Scrutinizer.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a copy of the Investors Presentation on Unadudited Financial Results for the Quarter ended June 30, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding Re-Schedulement of the Conference Call.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange regarding the Intimation of Conference Call.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange a Copy of the Limited Review Report.

Dishman Pharmaceuticals and Chemicals Limited has submitted to the Exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended June 30, 2016.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the trading window shall remain closed from July 26, 2016 to August 05, 2016 (both days inclusive) for all the connected persons.

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange that the Company's wholly owned subsidiary, namely Carbogen Amcis AG., Switzerland, had successfully completed US FDA lnspection for its two sites located at Aarau and Neuland without any adverse observations and received the Establishment lnspection Report (ElR) for the same. Thus, now the company has the above two sites in addition to Bubendorf in Switzerland, which are approved by the USFDA. Additlonally, the company's site at Naroda had also successfully completed USFDA lnspection and received the Establishment lnspect

Dishman Pharmaceuticals and Chemicals Limited has submitted the Exchange a News Paper Cuttings of Notice Of Court Convened Meeting of Equity Shareholders and Creditors (Secured And Un-Secured) for Scheme of Arrangement and Amalgamation

Dishman Pharmaceuticals and Chemicals Limited has informed the Exchange the renewal of US FDA inspection of Company's Bavla facility has been successfully completed on July 08, 2016.